Evox Therapeutics Ltd
USPTO PatentsView assignee record - 6 granted patents across 8 technology areas, recorded in grant years 2022–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).
The verdict
According to USPTO PatentsView, Evox ranks #40,127 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 8 technology areas.
- #40,127
- of 49,997 US assignees by volume
- Top 30%
- by Innovation Score (42.7/100)
- 10.0
- avg claims per patent
USPTO PatentsView assignee plate
Corpus R40127 · Foreign Corporation #40,127 · 6 grants
GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-PAR · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH
- GRANTS-MICRO 6 grants
- LOWER-Q #40,127/49,997
- PHOTO-FINISH Evofem
- CPC-NARROW A61K · 8 areas
- INNOV-PAR 42.7/100
- CLAIMS-PAR 10.0 claims/avg
- TYPE-FRNCORP Foreign Corp
- SPAN-YRS 2022–2024 · 3y
- BOOK-RICH 9/10 fields
Nearest grant-volume peer: Evofem, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Evox’s 42.7 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Evox
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Evox Therapeutics · this assignee
Evox Therapeutics · this assignee
43 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Evox's Innovation Score is 42.7/100 (top 30% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Evox?
Each dot is one of Evox’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Evox’s own 10.0 claims/patent is at or below the 14.2 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where Evox's grants concentrate
Evox Therapeutics Ltd is a focused PatentsView assignee: 8 CPC subclasses with 100% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2022 (4 grants) versus a trough of 1 in 2023. By volume, Evox sits between Evofem, Inc. and Exactration, LLC.
Evox's three-year grant acceleration
Evox Therapeutics Ltd shows 6 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Evox's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Evofem
Evofem, Inc.
6 patents
- Evolve Range Solu…
Evolve Range Solutions, Inc.
6 patents
- Evonik Specialty…
Evonik Specialty Chemicals (Shanghai) Co., Ltd.
6 patents
- Evosport AB
Evosport AB
6 patents
- Exb Asset Managem…
ExB Asset Management GmbH
6 patents
- Exq
ExQ, LLC
6 patents
- Exacttarget
ExactTarget, Inc.
6 patents
- Exactration
Exactration, LLC
6 patents
- Evox Therapeutics ◀
Evox Therapeutics Ltd
6 patents
What this shows Evox holds 6 patents at rank #40,123, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Evox
By rank, the assignees closest to #40,123 in granted patent volume.
- Evofem, Inc. #40,119 · 6 patents
- Evolve Range Solutions, Inc. #40,120 · 6 patents
- Evonik Specialty Chemicals (Shanghai) Co., Ltd. #40,121 · 6 patents
- Evosport AB #40,122 · 6 patents
- ExB Asset Management GmbH #40,124 · 6 patents
- ExQ, LLC #40,125 · 6 patents
- ExactTarget, Inc. #40,126 · 6 patents
- Exactration, LLC #40,127 · 6 patents
Leaders in A61K (Preparations FOR Medical)
Other assignees with the most granted patents in Evox's primary technology class.
- The Regents of the University of California 1,779 in class
- L'Oreal 1,250 in class
- Novartis AG 988 in class
- The Procter & Gamble Company 985 in class
- The Board of Regents of the University of Texas System 950 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 813 in class
- The Trustees of the University of Pennsylvania 768 in class
- Merck Sharp & Dohme LLC 760 in class
Evox's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
43 Top 30% higher than 70% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2022 | 4 | 66.7% |
| 2023 | 1 | 16.7% |
| 2024 | 1 | 16.7% |
Which technologies does Evox Therapeutics Ltd patent most?
Top 8 of 8 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Evox Therapeutics Ltd's patent record in context - here's where to go next.
- Evox Therapeutics Ltd's lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 100% of its portfolio - see every assignee active in that class. Explore A61K
- Ranked #40,127 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Evox Therapeutics Ltd against Evofem, Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 42.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.